October 4, 2016
AstraZeneca-s Brilianta drug fails in big arterial disease trial
AstraZeneca’s heart drug Brilinta has failed to help patients with serious circulatory problems in their legs, dealing a blow to a medicine that the company has tipped as a potential $3.5 billion-a-year seller by 2023.